<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572542</url>
  </required_header>
  <id_info>
    <org_study_id>Arise-FJ-G202</org_study_id>
    <nct_id>NCT04572542</nct_id>
  </id_info>
  <brief_title>Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer</brief_title>
  <official_title>Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer： a Single-arm, Multicenter， Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate&#xD;
      and nab-paclitaxel .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>one year</time_frame>
    <description>Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate（DCR）</measure>
    <time_frame>one year</time_frame>
    <description>Disease Control Rate（DCR） according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Locally Advanced or Metastatic Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Camrelizumab combined with Apatinib mesylate tablets and nab-paclitaxel in the second-line treatment of advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab One course will last 21 days.Given once every 3 weeks at a dose of 200 mg</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>Apatinib One course will last 21 days.Oral administration at a dose of 250 mg everyday</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-paclitaxel</intervention_name>
    <description>nab-paclitaxel One course will last 21 days。Given twice every 3 weeks at a dose of 125 mg/m2</description>
    <arm_group_label>Camrelizumab + Apatinib + nab-paclitaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years of age&#xD;
&#xD;
          -  Gastric adenocarcinoma (papillary adenocarcinoma pap, tubular adenocarcinoma tub,&#xD;
             mucinous adenocarcinoma muc, sig-ring cell carcinoma sig, poorly differentiated&#xD;
             adenocarcinoma por) confirmed by pathology (including histology or cytology) is an&#xD;
             unresectable locally advanced or metastatic (stage IV) tumor.&#xD;
&#xD;
          -  For patients with advanced gastric cancer who had received standard first-line&#xD;
             treatment in the past, the interval of the last chemotherapy should be more than 1&#xD;
             month .&#xD;
&#xD;
          -  Measurable lesions at least should be detected by CT/MRI examination in accordance&#xD;
             with the RECIST1.1.（CT scan of tumor lesion length≥10mm，CT scan short&#xD;
             diameter≥15mm，scan slice thicknes 5mm）.&#xD;
&#xD;
          -  ECOG（Eastern Cooperative Oncology Group）:0-2 scores.&#xD;
&#xD;
          -  The expected survival time is more than 3 months.&#xD;
&#xD;
          -  The damage caused by subjects receiving other treatments has recovered, including&#xD;
             receiving nitroso or mitomycin at intervals &gt;=6 weeks; Received other cytotoxic drugs,&#xD;
             radiotherapy or surgery &gt;=4 weeks, and the wound had completely healed .&#xD;
&#xD;
          -  Patients with adequate organ function at the time of enrollment as defined below:&#xD;
&#xD;
               1. Blood routine examination standard (without blood transfusion within 14 days&#xD;
                  before enrollment):&#xD;
&#xD;
                    1. HB &gt;=90g/L;&#xD;
&#xD;
                    2. WBC &gt;=3.5x10^9/L;&#xD;
&#xD;
                    3. ANC &gt;=1.5x10^9/L;&#xD;
&#xD;
                    4. PLT &gt;=75x10^9/L;&#xD;
&#xD;
               2. Biochemical examination shall meet the following standards: a.BIL &lt;1.25 ULN;&#xD;
                  b.ALT and AST&lt; 2.5 ULN; If liver metastasis is present ALT and AST&lt; 5 ULN;&#xD;
                  c.Serum creatinine Cr &lt;=1 ULN; Serum creatinine &gt;50ml/min (Cockcroft-Gault math);&#xD;
&#xD;
          -  Women of childbearing age must have a pregnancy test in 7 days before entering the&#xD;
             group (in serum), and the results were negative, and willing to use appropriate&#xD;
             contraception during the study period and the last 8 weeks after giving drug test; men&#xD;
             should have the surgical sterilization, or adopt the appropriate contraceptive methods&#xD;
             during the test and the last 8 weeks after giving drug test.&#xD;
&#xD;
          -  Participants is willing to participate in this study, sign the informed consent, have&#xD;
             good compliance, cooperate with follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with chemotherapy and contraindications to Apatinib mesylate.&#xD;
&#xD;
          -  Previous history of receiving purpuranoidins, Apatinib mesylate or other&#xD;
             antiangiogenic drugs, Camrelizumab or other immunotherapy.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Those who participated in other clinical studies and did not recover from toxic&#xD;
             reactions within 1 month before enrollment.&#xD;
&#xD;
          -  Except for other malignant tumors, basal cell carcinoma of the skin and cervical&#xD;
             cancer in situ in the past 5 years.&#xD;
&#xD;
          -  Accompanied by serious heart, lung, liver, kidney disease; Have nerve, mental disease;&#xD;
             Jaundice or obstruction of the digestive tract with severe infection&#xD;
&#xD;
          -  The presence of uncontrolled or symptomatic active central nervous system (CNS)&#xD;
             metastases may manifest as the presence of clinical symptoms, cerebral edema, spinal&#xD;
             cord compression meningitis, ptosis, and/or progressive growth. After adequate&#xD;
             treatment for CNS metastases, neurological symptoms can return to baseline at least 2&#xD;
             weeks prior to randomization (residual signs or symptoms associated with CNS treatment&#xD;
             can be enrolled in the study. In addition, subjects must either discontinue&#xD;
             corticosteroids or receive prednisone (or an equivalent dose of other corticosteroids)&#xD;
             at a steady dose of ≤ 10 mg/d or a gradually reduced dose for at least 2 weeks prior&#xD;
             to randomization.&#xD;
&#xD;
          -  The blood pressure of patients with hypertension cannot be reduced to the normal range&#xD;
             by the antihypertensive drugs (systolic pressure &gt;140 mmHg, diastolic pressure &gt;90&#xD;
             mmHg)&#xD;
&#xD;
          -  With Ⅰ magnitude of coronary heart disease, arrhythmia (including QTc protracted&#xD;
             between male &gt; 450 ms, women &gt; 470 ms) and cardiac insufficiency&#xD;
&#xD;
          -  Patients have a clear tendency with gastrointestinal bleeding, including the following&#xD;
             situation: local active ulcerative lesions, and fecal occult blood (+ +); with melena&#xD;
             and hematemesis history in 2 months; and patients with fecal occult blood (+) and&#xD;
             unresected gastric primary tumor; patients with the risk of bleeding should take the&#xD;
             gastroscopy test, if it is the gastric cancer, and researchers believe that may&#xD;
             results in massive digestive tract hemorrhage；coagulation dysfunction&#xD;
             (INR(international normalized ratio)&gt;1.5, APTT(activated partial thromboplastin&#xD;
             time)&gt;1.5 ULN), with bleeding tendency;&#xD;
&#xD;
          -  Patients with a history of cardiovascular and cerebrovascular diseases who are still&#xD;
             taking oral thrombolytic drugs or anticoagulant drugs&#xD;
&#xD;
          -  Patients are positive of urine protein (urine protein detection 2+ or above, or 24&#xD;
             hours urine protein quantitative &gt;1.0g).&#xD;
&#xD;
          -  Presence of any active, known or suspected autoimmune disease. Allowed to be included&#xD;
             in a stable state, do not need systemic immunosuppression treatment of subjects: such&#xD;
             as Ⅰ diabetes, only need to hormone replacement therapy for hypothyroidism and without&#xD;
             systemic treatment of skin disease (for example, vitiligo, psoriasis, and hair loss).&#xD;
&#xD;
          -  A history of immunodeficiency, including HIV testing positive, or other acquired or&#xD;
             congenital immunodeficiency disorders, or a history of organ transplantation and&#xD;
             allogeneic bone marrow transplantation.&#xD;
&#xD;
          -  Patients with other concomitant diseases that, at the investigator's discretion, pose&#xD;
             a serious risk to patient safety or affect patient completion of the study.&#xD;
&#xD;
          -  Patients with uncontrolled epilepsy, central nervous system disease, or mental&#xD;
             disorders whose clinical severity, as determined by the investigator, may prevent the&#xD;
             signing of the informed consent or have multiple factors that affect oral medications&#xD;
             (such as inability to swallow, persistent uncontrolled nausea and vomiting, chronic&#xD;
             diarrhea, and intestinal obstruction).&#xD;
&#xD;
          -  A person who has previously been allergic to any component of Camrelizumab or to any&#xD;
             component of the drug under study.&#xD;
&#xD;
          -  The researchers consider those who were not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ye feng, Doctor</last_name>
    <phone>13860458889</phone>
    <email>yefengdoctor@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li jia yi, Doctor</last_name>
    <phone>13799792820</phone>
    <email>ljy778848@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ye feng, Doctor</last_name>
      <phone>13860458889</phone>
      <email>yefengdoctor@sina.com</email>
    </contact>
    <investigator>
      <last_name>Ye feng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>LI jia yi, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 25, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>September 25, 2020</last_update_submitted>
  <last_update_submitted_qc>September 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

